<DOC>
	<DOC>NCT01135914</DOC>
	<brief_summary>To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in comparison with the current standard of care (laser photocoagulation monotherapy), in patients with visual impairment due to DME.</brief_summary>
	<brief_title>Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Stable Type 1 or Type 2 diabetes mellitus Visual impairment due to focal or diffuse DME in at least one eye Active conditions in the study eye that could prevent the improvement of visual acuity on study treatment Active eye infection or inflammation History of stroke, renal failure or uncontrolled hypertension Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>DME</keyword>
	<keyword>visual impairment</keyword>
	<keyword>diabetes</keyword>
	<keyword>macular edema</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>laser</keyword>
	<keyword>photocoagulation</keyword>
	<keyword>retinopathy</keyword>
	<keyword>retina</keyword>
</DOC>